Petrovska Ia, Tsvetkova L, Petrova O
Ter Arkh. 1990;62(3):72-5.
Twenty patients with infectious allergic bronchial asthma were treated for 4 months with the polybacterial immunostimulator Respivax combined with the maintenance therapy using corticosteroids and bronchospasmolytics. The results show a considerable improvement of the clinical parameters on days 45, 120 and 240 of the treatment. The spirometric indicators improved in more than 50% of the patients. Study of the immune parameters in the serum and saliva indicates an appreciable lowering of the activity of the inflammatory response in the bronchial mucosa, improvement of the specific and nonspecific immune parameters and noticeable positive dynamics of cellular immunity.
20例感染性过敏性支气管哮喘患者接受了多细菌免疫刺激剂Respivax治疗4个月，并联合使用皮质类固醇和支气管解痉剂进行维持治疗。结果显示，在治疗的第45、120和240天，临床参数有显著改善。超过50%的患者肺功能指标得到改善。对血清和唾液中免疫参数的研究表明，支气管黏膜炎症反应活性明显降低，特异性和非特异性免疫参数得到改善，细胞免疫呈现明显的正向动态变化。
